Should I buy or sell GSK stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares. View GSK analyst ratings or view top-rated stocks .

What is GSK's stock price target for 2024?

7 brokers have issued twelve-month target prices for GSK's stock. Their GSK share price targets range from GBX 1,300 to GBX 1,950. On average, they predict the company's stock price to reach GBX 1,630.63 in the next twelve months. This suggests that the stock has a possible downside of 0.8%. View analysts price targets for GSK or view top-rated stocks among Wall Street analysts .

How have GSK shares performed in 2024?

GSK's stock was trading at GBX 1,450.20 at the start of the year. Since then, GSK shares have increased by 13.3% and is now trading at GBX 1,643.50. View the best growth stocks for 2024 here .

How were GSK's earnings last quarter?

GSK plc (LON:GSK) posted its quarterly earnings data on Wednesday, July, 29th. The company reported $56.90 EPS for the quarter. GSK had a trailing twelve-month return on equity of 46.38% and a net margin of 16.25%.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK declared a dividend on Wednesday, January 31st. Stockholders of record on Thursday, February 22nd will be paid a dividend of GBX 16 per share on Thursday, April 11th. This represents a dividend yield of 1.04%. The ex-dividend date is Thursday, February 22nd. This is an increase from the stock's previous dividend of GBX 14. The official announcement can be accessed at this link . Read our dividend analysis for GSK .

Is GSK a good dividend stock?

GSK (LON:GSK) pays an annual dividend of GBX 64 per share and currently has a dividend yield of 3.95%. The dividend payout ratio is 5,333.33%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for GSK .

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AstraZeneca (AZN) , General Electric (GE) , Royal Dutch Shell (RDSB) , Vodafone Group Public (VOD) , Intel (INTC) , NVIDIA (NVDA) , Johnson & Johnson (JNJ) , AT&T (T) , Barclays (BARC) and Gilead Sciences (GILD) .

How do I buy shares of GSK?

Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:GSK

GSK (GSK) Share Price, News & Analysis

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

Free GSK Stock Alerts

GBX 1,643.50

0.00 (0.00%)

(As of 04/15/2024 ET)

Compare

Today's Range: 1,631
▼
1,648
50-Day Range: 1,610.68
▼
1,711.20
52-Week Range: 1,302.60
▼
1,719.80

Volume: 3.21 million shs
Average Volume: 7.15 million shs
Market Capitalization: £67.22 billion

P/E Ratio: 1,369.58
Dividend Yield: 3.89%
Price Target: GBX 1,630.63

Stock Analysis Analyst Forecasts Chart Competitors Dividend Headlines Insider Trades Sustainability

Get GSK alerts:

GSK MarketRank™ Stock Analysis

Analyst Rating: Hold
2.29 Rating Score
Upside/Downside: 0.8% Downside
GBX 1,630.63 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: -1.56
Upright™ Environmental Score
News Sentiment: 0.34
Based on 7 Articles This Week
Insider Trading: Selling Shares
£231.78 M Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.81 out of 5 stars

1.1

Analyst's Opinion

Consensus Rating
GSK has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 3 buy ratings, 3 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
GSK has only been the subject of 4 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for GSK.

1.7

Dividend Strength

Dividend Leadership
GSK is a leading dividend payer. It pays a dividend yield of 3.95%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
GSK does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of GSK is 5,333.33%. Payout ratios above 75% are not desirable because they may not be sustainable.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
GSK has received a 66.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "HIV medication", "Shingles vaccines", "Mouthwash", "Clinical research services for infectious diseases", "Clinical research services for cancer", and "Clinical research services for the respiratory system" products. See details.
Environmental Sustainability
The Environmental Impact score for GSK is -1.56.

1.9

News and Social Media Coverage

News Sentiment
GSK has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for GSK this week, compared to 7 articles on an average week.
Search Interest
Only 31 people have searched for GSK on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.
MarketBeat Follows
5 people have added GSK to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GSK insiders have sold 638.57% more of their company's stock than they have bought. Specifically, they have bought £313,814.84 in company stock and sold £2,317,751.36 in company stock.
Percentage Held by Insiders
Only 1.71% of the stock of GSK is held by insiders.
Percentage Held by Institutions
45.39% of the stock of GSK is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of GSK is 1,369.58, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 142.26.
Price to Earnings Ratio vs. Sector
The P/E ratio of GSK is 1,369.58, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 245.50.
Price to Earnings Growth Ratio
GSK has a PEG Ratio of 1.09. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
GSK has a P/B Ratio of 5.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Porter & Company

The #1 Investment of the Decade…

Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.

To get all the details of this controversial tech – click here now.

About GSK Stock (LON:GSK)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GSK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GSK Stock News Headlines

April 3, 2024 | marketbeat.com

Akebia Therapeutics Surges on FDA Approval for Anemia Treatment (GSK)

Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia

March 23, 2024 | insidertrades.com

Insider Buying: GSK plc (LON:GSK) Insider Buys 434 Shares of Stock

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

April 14, 2024 | americanbankingnews.com

GSK plc (LON:GSK) Given Consensus Recommendation of "Hold" by Analysts

April 12, 2024 | finance.yahoo.com

GSK plc: GSK's Strong Vaccine and HIV Portfolios Support Steady Growth

April 11, 2024 | msn.com

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields

April 11, 2024 | msn.com

Democrats push more drug makers to lower the price of inhalers

April 11, 2024 | forbes.com

Will Biopharma Companies Shun Vaccine R&D In A New Pandemic?

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

April 9, 2024 | americanbankingnews.com

Barclays Reiterates Equal Weight Rating for GSK (LON:GSK)

April 2, 2024 | markets.businessinsider.com

Buy Rating Affirmed for SCYNEXIS on Ibrexafungerp Success and Strong GSK Partnership

April 2, 2024 | seekingalpha.com

Scynexis: Update Following Restructuring Of GSK Deal

April 2, 2024 | seekingalpha.com

Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)

March 28, 2024 | bizjournals.com

Former GSK office building in Navy Yard set for sheriff's sale to satisfy $78M foreclosure judgment

March 21, 2024 | benzinga.com

Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month

March 20, 2024 | markets.businessinsider.com

Sosei Regains Full Ownership From GSK Of Clinic-Ready GPR35 Agonist For Inflammatory Bowel Disease

March 20, 2024 | reuters.com

GSK to cap out-of-pocket inhaler costs in US

March 18, 2024 | msn.com

GSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial Cancer

March 18, 2024 | lse.co.uk

GSK says Jemperli combination gets good results for endometrial cancer

March 18, 2024 | marketwatch.com

GSK's Endometrial Cancer Treatment Study Shows Combination Potential

March 9, 2024 | finance.yahoo.com

GSK Mar 2024 41.000 call

March 9, 2024 | finance.yahoo.com

GSK Mar 2024 34.000 put

March 7, 2024 | msn.com

GSK's Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage Study

March 7, 2024 | msn.com

GSK’s Blenrep combo therapy meets key goal in multiple myeloma trial

March 7, 2024 | msn.com

GSK's blood cancer drug meets main goal in late-stage trial; analysts tout comeback

March 6, 2024 | es-us.finanzas.yahoo.com

CORRECTED-GSK's new HIV drug formula could support longer dosing intervals (March 4)

March 6, 2024 | msn.com

WHO warns of growing resistance to GSK's HIV drug

See More Headlines

Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 7/29/2020
Ex-Dividend for 4/11 Dividend: 2/22/2024
Dividend Payable: 4/11/2024
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Sector: Medical
Industry: Drug Manufacturers - General
Sub-Industry: N/A
Current Symbol: LON:GSK
CUSIP: N/A
CIK: N/A
Web: www.gsk.com
Phone: +44-20-80475000
Fax: N/A
Employees: 70,212
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: GBX 1,630.63
High Stock Price Target: GBX 1,950
Low Stock Price Target: GBX 1,300
Potential Upside/Downside: -0.8%
Consensus Rating: Hold
Rating Score (0-4): 2.29
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): GBX 1.20
Trailing P/E Ratio: 1,369.58
Forward P/E Ratio: 10.42
P/E Growth: 1.09
Net Income: £4.93 billion
Net Margins: 16.25%
Pretax Margin: N/A
Return on Equity: 46.38%
Return on Assets: 8.81%

Debt

Debt-to-Equity Ratio: 140.82
Current Ratio: 0.88
Quick Ratio: 0.73

Sales & Book Value

Annual Sales: £30.33 billion
Price / Sales: 2.22
Cash Flow: GBX 201.77 per share
Price / Cash Flow: 8.15
Book Value: GBX 329 per share
Price / Book: 5.00

Miscellaneous

Outstanding Shares: 4,090,000,000
Free Float: N/A
Market Cap: £67.22 billion
Optionable: Not Optionable
Beta: 0.27

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Ms. Emma Natasha Walmsley (Age 55)
CEO & Director
Comp: $5.39M
Ms. Julie Belita Brown (Age 62)
CFO & Executive Director
Comp: $5.14M
Ms. Shobie Ramakrishnan (Age 53)
Chief Digital & Technology Officer
Mr. Tony Wood
Chief Scientific Officer and Head of R&D
Ms. Sarah Elton-Farr
Head of Investor Relations
Mr. James Ford
Senior VP & Group General Counsel of Legal & Compliance
Ms. Sally Jackson
Senior Vice President of Global Communications & CEO Office
Mr. David Simon Redfern BSc (Hons) (Age 58)
CA, President of Corporate Development
Ms. Diana Conrad
Chief People Officer
Mr. Philip C. Thomson
President of Global Affairs

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

Should I Buy GSK Stock? GSK Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in GSK plc:

GSK plc has shown consistent growth in revenue and earnings, indicating a strong financial performance.
The company has a solid return on equity of 51.45%, showcasing efficient utilization of shareholder funds.
With a market capitalization of $88.69 billion, GSK plc is a well-established player in the pharmaceutical industry.
GSK plc's stock price has been steadily increasing, reaching a 12-month high of $43.84, reflecting positive investor sentiment.
The company's diverse product portfolio and global presence provide stability and potential for further expansion.

Cons

Investors should be bearish about investing in GSK plc for these reasons:

GSK plc's PEG ratio of 1.94 suggests that the stock may be overvalued relative to its future growth prospects.
The company's debt-to-equity ratio of 1.19 indicates a relatively high level of debt, which could pose risks in a challenging economic environment.
Analysts predict a lower earnings per share of 4.08 for the current fiscal period, potentially impacting investor expectations.
GSK plc's beta of 0.64 implies lower volatility compared to the market, which may limit potential returns for more aggressive investors.
The company's quick ratio of 0.62 raises concerns about its short-term liquidity and ability to meet immediate financial obligations.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK Stock Analysis - Frequently Asked Questions

Should I buy or sell GSK stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings or view top-rated stocks.
What is GSK's stock price target for 2024?: 7 brokers have issued twelve-month target prices for GSK's stock. Their GSK share price targets range from GBX 1,300 to GBX 1,950. On average, they predict the company's stock price to reach GBX 1,630.63 in the next twelve months. This suggests that the stock has a possible downside of 0.8%.
View analysts price targets for GSK or view top-rated stocks among Wall Street analysts.
How have GSK shares performed in 2024?: GSK's stock was trading at GBX 1,450.20 at the start of the year. Since then, GSK shares have increased by 13.3% and is now trading at GBX 1,643.50.
View the best growth stocks for 2024 here.
How were GSK's earnings last quarter?: GSK plc (LON:GSK) posted its quarterly earnings data on Wednesday, July, 29th. The company reported $56.90 EPS for the quarter. GSK had a trailing twelve-month return on equity of 46.38% and a net margin of 16.25%.

How often does GSK pay dividends? What is the dividend yield for GSK?: GSK declared a dividend on Wednesday, January 31st. Stockholders of record on Thursday, February 22nd will be paid a dividend of GBX 16 per share on Thursday, April 11th. This represents a dividend yield of 1.04%. The ex-dividend date is Thursday, February 22nd. This is an increase from the stock's previous dividend of GBX 14. The official announcement can be accessed at this link.
Read our dividend analysis for GSK.
Is GSK a good dividend stock?: GSK (LON:GSK) pays an annual dividend of GBX 64 per share and currently has a dividend yield of 3.95%. The dividend payout ratio is 5,333.33%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for GSK.
What other stocks do shareholders of GSK own?: Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AstraZeneca (AZN), General Electric (GE), Royal Dutch Shell (RDSB), Vodafone Group Public (VOD), Intel (INTC), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), Barclays (BARC) and Gilead Sciences (GILD).
How do I buy shares of GSK?: Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:GSK) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

GSK (GSK) Share Price, News & Analysis

GSK MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About GSK Stock (LON:GSK)

GSK Stock Price History

GSK Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

Should I Buy GSK Stock? GSK Pros and Cons Explained

Pros

Cons

GSK Stock Analysis - Frequently Asked Questions

Overall MarketRank^™